Immunomedics (IMMU) Misses Q4 EPS by 46c

Immunomedics (NASDAQ: IMMU) reported Q4 EPS of ($0.68), $0.46 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $4.27 million.

For earnings history and earnings-related data on Immunomedics (IMMU) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• ACRES Commercial Realty says labor dispute is hindering hotel sale
• Navios Maritime Partners (NMM) Tops Q2 EPS by 34c